RESUMEN
AIM: The aim of this study was to identify factors predictive of serious infections over time in patients with systemic lupus erythematosus (SLE). METHODS: A multi-ethnic, multi-national Latin American SLE cohort was studied. Serious infection was defined as one that required hospitalization, occurred during a hospitalization or led to death. Potential predictors included were sociodemographic factors, clinical manifestations (per organ involved, lymphopenia and leukopenia, independently) and previous infections at baseline. Disease activity (SLEDAI), damage (SLICC/ACR Damage Index), non-serious infections, glucocorticoids, antimalarials (users and non-users), and immunosuppressive drugs use; the last six variables were examined as time-dependent covariates. Cox regression models were used to evaluate the predictors of serious infections using a backward elimination procedure. Univariable and multivariable analyses were performed. RESULTS: Of the 1243 patients included, 1116 (89.8%) were female. The median (interquartile range) age at diagnosis and follow-up time were 27 (20-37) years and 47.8 (17.9-68.6) months, respectively. The incidence rate of serious infections was 3.8 cases per 100 person-years. Antimalarial use (hazard ratio: 0.69; 95% confidence interval (CI): 0.48-0.99; p = 0.0440) was protective, while doses of prednisone >15 and ≤60 mg/day (hazard ratio: 4.18; 95 %CI: 1.69-10.31; p = 0.0019) and >60 mg/day (hazard ratio: 4.71; 95% CI: 1.35-16.49; p = 0.0153), use of methylprednisolone pulses (hazard ratio: 1.53; 95% CI: 1.10-2.13; p = 0.0124), increase in disease activity (hazard ratio: 1.03; 95% CI: 1.01-1.04; p = 0.0016) and damage accrual (hazard ratio: 1.22; 95% CI: 1.11-1.34; p < 0.0001) were predictive factors of serious infections. CONCLUSIONS: Over time, prednisone doses higher than 15 mg/day, use of methylprednisolone pulses, increase in disease activity and damage accrual were predictive of infections, whereas antimalarial use was protective against them in SLE patients.
Asunto(s)
Hospitalización/estadística & datos numéricos , Infecciones/epidemiología , Lupus Eritematoso Sistémico/tratamiento farmacológico , Adulto , Antimaláricos/administración & dosificación , Estudios de Cohortes , Relación Dosis-Respuesta a Droga , Femenino , Estudios de Seguimiento , Glucocorticoides/administración & dosificación , Humanos , Inmunosupresores/administración & dosificación , Infecciones/etiología , América Latina , Lupus Eritematoso Sistémico/fisiopatología , Masculino , Metilprednisolona/administración & dosificación , Prednisona/administración & dosificación , Factores Protectores , Factores de Riesgo , Índice de Severidad de la Enfermedad , Adulto JovenRESUMEN
Objectives The objectives of this study were to examine the demographic and clinical features associated with the occurrence of pleuropulmonary manifestations, the predictive factors of their occurrence and their impact on mortality in systemic lupus erythematosus (SLE) patients. Materials and methods The association of pleuropulmonary manifestations with demographic and clinical features, the predictive factors of their occurrence and their impact on mortality were examined in GLADEL patients by appropriate univariable and multivariable analyses. Results At least one pleuropulmonary manifestation occurred in 421 of the 1480 SLE patients (28.4%), pleurisy being the most frequent (24.0%). Age at SLE onset ≥30 years (OR 1.42; 95% CI 1.10-1.83), the presence of lower respiratory tract infection (OR 3.19; 95% CI 2.05-4.96), non-ischemic heart disease (OR 3.17; 95% CI 2.41-4.18), ischemic heart disease (OR 3.39; 95% CI 2.08-5.54), systemic (OR 2.00; 95% CI 1.37-2.91), ocular (OR 1.58; 95% CI 1.16-2.14) and renal manifestations (OR 1.44; 95% CI 1.09-1.83) were associated with pleuropulmonary manifestations, whereas cutaneous manifestations were negatively associated (OR 0.47; 95% CI 0.29-0.76). Non-ischemic heart disease (HR 2.24; 95% CI 1.63-3.09), SDI scores ≥1 (OR 1.54; 95% CI 1.10-2.17) and anti-La antibody positivity (OR 2.51; 95% CI 1.39-4.57) independently predicted their subsequent occurrence. Cutaneous manifestations were protective of the subsequent occurrence of pleuropulmonary manifestations (HR 0.62; 95% CI 0.43-0.90). Pleuropulmonary manifestations independently contributed a decreased survival (HR: 2.79 95% CI 1.80-4.31). Conclusion Pleuropulmonary manifestations are frequent in SLE, particularly pleuritis. Older age, respiratory tract infection, cardiac, systemic and renal involvement were associated with them, whereas cutaneous manifestations were negatively associated. Cardiac compromise, SDI scores ≥1 and anti-La positivity at disease onset were predictive of their subsequent occurrence, whereas cutaneous manifestations were protective. They independently contributed to a decreased survival in these patients.
Asunto(s)
Enfermedades Pulmonares/etiología , Lupus Eritematoso Sistémico/complicaciones , Pleuresia/etiología , Adulto , Estudios de Cohortes , Femenino , Humanos , Lupus Eritematoso Sistémico/mortalidad , Masculino , Infecciones del Sistema Respiratorio/etiología , Índice de Severidad de la EnfermedadRESUMEN
OBJECTIVES: The objective of this paper is to assess the predictors of time-to-lupus renal disease in Latin American patients. METHODS: Systemic lupus erythematosus (SLE) patients (n = 1480) from Grupo Latino Americano De Estudio de Lupus (GLADEL's) longitudinal inception cohort were studied. Endpoint was ACR renal criterion development after SLE diagnosis (prevalent cases excluded). Renal disease predictors were examined by univariable and multivariable Cox proportional hazards regression analyses. Antimalarials were considered time dependent in alternative analyses. RESULTS: Of the entire cohort, 265 patients (17.9%) developed renal disease after entering the cohort. Of them, 88 (33.2%) developed persistent proteinuria, 44 (16.6%) cellular casts and 133 (50.2%) both; 233 patients (87.9%) were women; mean (± SD) age at diagnosis was 28.0 (11.9) years; 12.2% were African-Latin Americans, 42.5% Mestizos, and 45.3% Caucasians (p = 0.0016). Mestizo ethnicity (HR 1.61, 95% CI 1.19-2.17), hypertension (HR 3.99, 95% CI 3.02-5.26) and SLEDAI at diagnosis (HR 1.04, 95% CI 1.01-1.06) were associated with a shorter time-to-renal disease occurrence; antimalarial use (HR 0.57, 95% CI 0.43-0.77), older age at onset (HR 0.90, 95% CI 0.85-0.95, for every five years) and photosensitivity (HR 0.74, 95% CI 0.56-0.98) were associated with a longer time. Alternative model results were consistent with the antimalarial protective effect (HR 0.70, 95% CI 0.50-0.99). CONCLUSIONS: Our data strongly support the fact that Mestizo patients are at increased risk of developing renal disease early while antimalarials seem to delay the appearance of this SLE manifestation. These data have important implications for the treatment of these patients regardless of their geographic location.
Asunto(s)
Antimaláricos/uso terapéutico , Lupus Eritematoso Sistémico/tratamiento farmacológico , Nefritis Lúpica/prevención & control , Adolescente , Adulto , Edad de Inicio , Antimaláricos/administración & dosificación , Estudios de Cohortes , Femenino , Estudios de Seguimiento , Humanos , Hipertensión/epidemiología , América Latina/epidemiología , Estudios Longitudinales , Lupus Eritematoso Sistémico/etnología , Lupus Eritematoso Sistémico/fisiopatología , Nefritis Lúpica/etnología , Masculino , Análisis Multivariante , Trastornos por Fotosensibilidad/epidemiología , Modelos de Riesgos Proporcionales , Análisis de Regresión , Factores de Riesgo , Índice de Severidad de la Enfermedad , Factores de Tiempo , Adulto JovenRESUMEN
OBJECTIVE: To determine the frequency and nature of clinical manifestations in Brazilian patients with systemic lupus erythematosus and Raynaud's phenomenon. METHODS: One hundred twenty-three patients with systemic lupus erythematosus (1982 American Rheumatism Association criteria) and Raynaud's phenomenon (at least two-phase, bilateral color reaction reported by the patient or observed by a physician) referred to the Rheumatology Unit of the Campinas University Hospital were retrospectively compared with 149 systemic lupus erythematosus patients without Raynaud's phenomenon. For each patient, gender, race, age at disease onset, disease duration, follow-up duration, clinical manifestations, and laboratory test findings were recorded. RESULTS: Patients with Raynaud's phenomenon were more likely to have skin lesions and/or myalgia/myopathy and less likely to have nephritis and nephrotic syndrome. All five patients with pulmonary hypertension also had Raynaud's phenomenon. Raynaud's phenomenon was less common in younger patients and more common in patients with alopecia. CONCLUSIONS: Raynaud's phenomenon was common in systemic lupus erythematosus patients from a tropical country. A better prognosis can be expected in lupus patients with Raynaud's phenomenon except when pulmonary hypertension occurs.
Asunto(s)
Lupus Eritematoso Sistémico/complicaciones , Enfermedad de Raynaud/complicaciones , Adolescente , Adulto , Factores de Edad , Edad de Inicio , Femenino , Estudios de Seguimiento , Humanos , Lupus Eritematoso Sistémico/epidemiología , Lupus Eritematoso Sistémico/fisiopatología , Masculino , Persona de Mediana Edad , Enfermedad de Raynaud/fisiopatología , Factores Sexuales , Factores de TiempoRESUMEN
A associacao de dermatopolimiosite e infeccao por Toxoplasma gondii ja foi relatada. Os autores julgam oportuno relatar a evolucao de um caso acometido por toxoplasmose congenita e dermatopolimiosite, tendo em conta a reagudizacao daquela e as eventuais implicacoes patogenicas
Asunto(s)
Dermatomiositis , Toxoplasmosis CongénitaRESUMEN
Os autores apresentam um caso de lupus eritematoso sistemico, caracterizado por dados clinicos e laboratoriais e que sua evolucao permitiu suspeitar da sindrome de Jaccoud associada. O diagnostico diferencial com a artrite reumatoide e assinalada pela presenca de deformidade das maos, embora com preservacao da funcao e o exame radiologico na sindrome de Jaccoud nao mostre lesoes erosivas
Asunto(s)
Artritis , Lupus Eritematoso Sistémico , Cardiopatía ReumáticaRESUMEN
Os autores apresentam um caso de mielite transversa associada a comprometimento do sistema nervoso central, que ocorreu na vigencia de um caso mal definido de lupus eritomatoso sitematizado. Na evolucao surgiram elementos clinicos e laboratoriais de doenca mista do tecido conjuntivo, com altos titulos de anti-ENA. Foi tratada com "pulse" de metilprednisolona, resolvendo-se o quadro nervoso central, mantendo-se porem sequela da mielite transversa. Discutem a existencia de quadro neurologico semelhante na DMTC, apesar da presenca de anti-Sm